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Therapeutic resistanceAbstract As a leading cause of cancer deaths worldwide, lung cancer is a collection of diseases
with diverse etiologies which can be broadly classified into small-cell lung cancer (SCLC) and
non-small-cell lung cancer (NSCLC). Lung cancer is characterized by genomic and epigenomic alter-
ations; however, mechanisms underlying lung tumorigenesis remain to be elucidated. Long non-
coding RNAs (lncRNAs) are a group of non-coding RNAs that consist of P200 nucleotides but
possess low or no protein-coding potential. Accumulating evidence indicates that abnormal expres-
sion of lncRNAs is associated with tumorigenesis of various cancers, including lung cancer, through
multiple biological mechanisms involving epigenetic, transcriptional, and post-transcriptional alter-
ations. In this review, we highlight the expression and roles of lncRNAs in NSCLC and discuss their
potential clinical applications as diagnostic or prognostic biomarkers, as well as therapeutic targets.Introduction
Lung cancer is the most common cancer and the leading cause
of cancer deaths among men and women worldwide. Among
all lung cancer cases, non-small-cell lung cancers (NSCLCs)
account for approximately 85% [1], which are at locally
advanced or metastatic stage at diagnosis [2]. Based on its
pathological characteristics, NSCLC is subdivided into three
subtypes, namely, lung adenocarcinoma (LAD), large cellcarcinoma (LCC), and lung squamous cell carcinoma (LSCC).
LAD and LSCC are the predominant types of NSCLCs, which
constitute 50% and 40% of NSCLC cases, respectively [3].
Although the traditional therapeutic strategies have been
tremendously improved and targeted therapies, such as tyro-
sine kinase inhibitors (TKIs) of the epidermal growth factor
receptor (EGFR) [4] and immune checkpoint inhibitors, have
been successfully used in clinical practice [5], the five-year over-
all survival rate of lung cancer of all stages combined remains
as low as 15.9% [6]. Such unfavorable outcome could be at
least partially attributed to the poor understanding of the
pathogenesis of NSCLC, as well as lack of early diagnostic
biomarkers and therapeutic targets.
Genetic and epigenetic alterations have been widely recog-
nized as the driving events of cancer. A recent high-throughput
transcriptome analysis showed that nearly 75% of the humannces and
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ome serves as blueprints for proteins with others as non-
coding RNAs (ncRNAs) [7]. ncRNAs can be short or small
(<200 bp) or long (P200 bp) in length. Small ncRNAs
include microRNAs (miRNAs), small interfering RNA (siR-
NAs), PIWI-interacting RNAs (piRNAs), as well as classical
housekeeping ncRNAs such as tRNAs, rRNAs, small nuclear
RNAs (snRNAs), and small nucleolar RNAs (snoRNAs).
miRNAs and piRNAs have been implicated in multiple cellu-
lar functions that are essential for physiological or pathologi-
cal processes [8]. Linearized ncRNAs containing >200
nucleotides are termed as long ncRNAs (lncRNAs), which
have attracted much attention recently. A wealth of compelling
evidence has demonstrated that aberrantly expressed lncRNAs
play important roles in cancer development, including cancer
cell proliferation and metastasis, through distinct transcrip-
tional, post-transcriptional, or epigenetic mechanisms [9,10].
In this review, we focus on the roles of lncRNAs in lung
tumorigenesis and briefly introduce the development of
lncRNA-directed diagnostics, prognostics and therapeutics.
Discovery of lncRNAs
The discovery of lncRNAs is attributed to studies on the size,
evolution, and function of the genome. Higher species were
previously thought to need more genes than lower species
[11]. However, developmental complexity of animals is not
determined by the amount of DNA in the genome [12]. For
example, the genome of salamander is 15 times larger than that
of humans [13]. With the aid of DNA–RNA hybridization
technique, scientists have come to realize that most parts of
the genome do not encode proteins and these non-coding
regions of the genome were considered as ‘‘junk DNA” [14].
On the other hand, some researchers reckoned that junk
DNA was not completely useless [11]. Therefore, substantial
interest has been focused on determining the functional roles
of these non-coding sequences. As a result, heterogeneous
nuclear RNAs and introns were discovered in the 1970s
[15–17]. Subsequent studies demonstrated that snRNAs and
snoRNAs play important roles in post-transcriptional RNA
processing [18], thus pushing forward investigations on other
non-coding sequences. In the early 1990s, the roles of some
lncRNAs (e.g., H19 and Xist) in epigenetic regulation were
uncovered [19–21]. However, research on lncRNAs was
suspended due to the discovery of miRNAs in 1993 [22] and
sustaining keen interests in microRNA studies. Notably, intro-
duction of whole-transcriptome sequencing in the early 2000s
led to the identification and annotation of many lncRNAs
[23–25]. A small number of characterized human lncRNAs
were then recognized as the central regulators of a variety of
biological processes including gene expression, mRNA pro-
cessing, and protein translation or transport [26]. Up till
now, ten thousands of lncRNAs have been identified in differ-
ent species. However, functional identification of lncRNAs
remains a gigantic challenge.
Characteristics of lncRNAs
lncRNAs contain P200 nucleotides and bear no or low
translational potential [9]. Based on their relationships withprotein-coding genes, lncRNAs are classified into six broad
categories, namely, intergenic, bidirectional, intron sense-
overlapping, exon sense-overlapping, intronic-antisense, and
natural-antisense lncRNAs [27] (Figure 1). lncRNAs usually
are transcribed by RNA polymerase II (RNAPII), but there
are some exceptions. For instance, brain-associated BC200 is
transcribed by RNAPIII [28]. Generally, lncRNAs are
expressed at lower levels and are less conserved than protein-
coding genes [29–31] and some lncRNAs exhibit cell-, tissue-
and time-specific expression patterns [32]. A growing body of
evidence has indicated that the expression of lncRNAs is tightly
regulated through distinct mechanisms, such as chromatin
state, transcription factors (TFs), and microRNAs [33]. And
majority of lncRNAs are transcribed from antisense regions
upstream of promoters, intragenic regions, intergenic regions
distal to promoters, or gene bodies of protein-coding genes [7].
Functions of lncRNAs
LncRNAs function in diverse biological processes by modulat-
ing the transcription and translation of protein-coding genes.
Unlike miRNAs, which commonly participate in mRNA
degradation or regulate mRNA translation [34–36], lncRNAs
regulate the expression of target genes through multiple mech-
anisms at different levels (Figure 2). lncRNAs can interact
directly with DNA, mRNA, or proteins to regulate chromatin
modification or structure, transcription, splicing, and transla-
tion, so as to regulate a variety of physiological and patholog-
ical processes such as cell proliferation or differentiation,
stem cell reprogramming, tumorigenesis, or drug resistance
[10,37,38]. Functions of lncRNAs are summarized in Figure 2
and briefly described below.
First, at the transcriptional level, lncRNAs (i) act as decoys
for TFs or RNAPII to disrupt their binding to promoters/
enhancers of target genes, thus promoting or suppressing gene
expression [39]; (ii) interact directly with TFs and alter their
modification or localization to regulate gene transcription
[40]; (iii) interact with DNA and form scaffolds for TFs, thus
affecting target gene transcription [41]; and (iv) act as compet-
itive endogenous RNAs (ceRNAs) to control target gene
transcription [42].
Second, at the post-transcriptional level, lncRNAs (i) act as
precursors of siRNAs or miRNAs, leading to decreased
expression of their target genes [43], (ii) form double-
stranded RNA complexes with mRNAs and protect them from
degradation [44], and (iii) regulate the alternative splicing of
pre-mRNAs to produce different transcripts [45].
Lastly, at the epigenetic level, lncRNAs (i) interact with
proteins associated with histone modifications to modify the
methylation, acetylation or ubiquitination of histones [46];
(ii) get involved in gene silencing by regulating DNA methyla-
tion in the promoter region of target genes [47]; and (iii) get
involved in chromatin remodeling or conformational alter-
ations by binding to chromatin modification complexes, which
is important for gene transcription [7].
Expression spectrum of lncRNAs in NSCLCs
Compelling evidence has demonstrated the important roles of
lncRNAs in various diseases, particularly in cancer. Recent
Figure 2 Molecular mechanisms for the functions of lncRNAs
① lncRNA acts as decoys for TFs or RNAPII; ② lncRNA alters the modification and location of transcription factors; ③ lncRNA
interacts with DNA and forms triple helix structures, thereby recruiting transcriptional complex; ④ lncRNA acts as decoy for miRNA;
⑤ lncRNA acts as precursor for siRNAs or miRNAs;⑥ lncRNA regulates the alternative splicing of pre-mRNAs through SR complex;
⑦ lncRNA protects mRNA from degradation through forming double-stranded RNA with mRNAs; ⑧ lncRNA regulates histone
modification by interacting with modification factors;⑨ lncRNA binds to DNA modification factors to modify the methylation of DNA;
⑩ lncRNA binds to chromatin modification complexes to regulate chromatin remodeling and structure. DNAMF: DNA modification
factor; HMF: histone modification factor; miRNA, microRNA; siRNA, small-interfering RNA; TF, transcription factor; RNAPII, RNA
polymerase II.
Figure 1 A diagram of lncRNA categories
Intergenic: a lncRNA gene lies as an independent unit within the genomic interval between two genes. Bidirectional: expression of a
lncRNA gene and its neighboring coding transcript on the opposite strand is initiated in close genomic proximity. Intron sense-
overlapping: a lncRNA gene lies in the intron of a protein-coding gene on the same strand. Exon sense-overlapping: a lncRNA gene lies in
the exons of protein-coding gene on the same strand. Intronic-antisense: a lncRNA lies in the introns of protein-coding gene on the
opposite strand in the same region. Natural-antisense: a lncRNA gene lies in the exons of protein-coding gene on the opposite strand.
lncRNA, long non-coding RNA.
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Wei MM and Zhou GB / lncRNAs in Lung Cancer 283studies have reported lncRNA expression in NSCLCs. For
instance, using high-throughput microarrays, Xu et al identi-
fied 2420 lncRNAs that were differentially expressed (fold
change P2) between LAD and normal tissue (NT) samples.
Of these 2420 lncRNAs, the expression of 1213 lncRNAs
was upregulated, whereas the expression of the remaining
1207 lncRNAs was downregulated [48]. As another example,
Yang et al identified 47 lncRNAs (14 upregulated and 33
downregulated lncRNAs) from gene expression data of five
NSCLC cohorts that were deposited in the Gene Expression
Omnibus (GEO) database [49]. Interestingly, several novel
lncRNAs were identified to be induced by established risk fac-
tors for NSCLC, such as cigarette smoking or exposure to a
polycyclic aromatic hydrocarbon compound benzo(a)pyrene
(BaP). These include cancer-associated lncRNA-1 (SCAL1),
DQ786227, and LOC728228 [50–52]. We recently reported
the screening for lncRNAs with abnormal expression in lung
cancers that are associated with air pollution [53]. We found
that the cancer samples of patients from high pollution region
had much more dysregulated lncRNAs than patients from
control regions when compared to their corresponding neigh-
boring tissues. Among these, the expression of an lncRNA,
CAR intergenic 10 (CAR10), was up-regulated in air
pollution-related NSCLCs. Expression of CAR10 could be
upregulated by the carcinogen dibenz[a,h]anthracene (DBA)
through increasing expression of TF FoxF2. CAR10 binds to
and stabilizes TF Y-box-binding protein 1 (YB-1), leading to
up-regulation of EGFR and proliferation of lung cancer cells.
Knockdown of CAR10 inhibited cell growth in vitro and
in vivo, suggesting the role of lncRNAs in environmental lung
carcinogenesis [53]. To gain new insights into the pathogenesis
of NSCLCs, the molecular mechanisms underlying the roles of
several lncRNAs such as MALAT1, HOTAIR, H19, and
PVT1 have been extensively investigated. We list the majority
of known NSCLC-associated lncRNAs and their functions in
Table 1. Their potential application as early diagnostic or
prognostic biomarkers and efficient therapeutic targets in
patients with NSCLCs warrants further investigations.
lncRNAs as biomarkers of NSCLCs
To improve overall survivals of patients, it is important to
exploit new biomarkers for diagnosing, subtyping, and prog-
nosing of NSCLCs. More and more studies have been focused
on ncRNAs, particularly miRNAs in the past few years [83].
Likewise, studies have indicated that aberrant expression of
lncRNAs is also a hallmark of carcinomas and some lncRNAs
show tissue- or cell-specific expression pattern [84], suggesting
their potentials as biomarkers. Several lncRNAs have been
reported as candidate biomarkers, e.g., highly up-regulated
in liver cancer (HULC) in human hepatocellular carcinoma
[85] and prostate cancer gene 3 (PCA3) in prostate cancer
[86]. Notably, many dysregulated lncRNAs have been identi-
fied in patients with NSCLCs (Table 1), suggesting that
lncRNAs could be used for screening effective and specific
biomarkers of NSCLCs.
To screen for lncRNAs as biomarkers for LADs at early-
stage, Li et al summarized microarray data of 181 patients with
early-stage LADs to examine their lncRNA expression
profiles. As a result, they found that LINC00313 was
highly expressed in patients with T2- and N1-stage LADs[87]. Therefore, LINC00313 could be used as a diagnostic
biomarker of early-stage LADs. lncRNAs can be detected in
serum, which makes it easier for clinical applications. Hence,
researchers put more emphasis on circulating lncRNAs.
As a results, MALAT1 [88], XIST, and HIF1A-AS1 [89] were
found overexpressed in NSCLC patients’ serum when com-
pared with controls. These lncRNAs may act as diagnosis
biomarkers for screening NSCLCs via peripheral blood
detection.
Subtyping of NSCLC cases is important for the selection of
clinical treatment options. For instance, patients with LAD
and LSCC differ in clinical outcomes. Zhao et al identified
72 differentially-expressed (23 upregulated and 49 downregu-
lated) lncRNAs in patients with LADs and LSCCs by using
human Affymetrix microarrays (HGU133plus2.0) [90]. Like-
wise, White et al identified 27 lung cancer-associated lncRNAs,
which could be used as novel biomarkers for stratifying LADs
and LSCCs [91]. Zhang et al found that expression of a novel
lncRNA, LINC01133, was upregulated in LSCC but not in
LAD samples [92]. All these findings indicate that some
lncRNAs could serve as potential biomarkers for distinguish-
ing subgroup of NSCLCs.
lncRNAs could also be used as prognostic biomarkers in
patients with NSCLCs. For instance, expression levels of
lncRNAs RP11-21L23.2, GPR158-AS1, RP11-701P16.5, and
RP11-379F4.4 were negatively correlated with NSCLC
patients’ overall survival. Conversely, expression levels of
lncRNAs CTD-2358C21.4, RP11-94L15.2, KCNK15-AS1,
and AC104134.2 were positively associated with the overall
survival of NSCLC patients [93].
The observations above indicate that despite their obscure
roles in lung tumorigenesis, these lncRNAs may be valuable
for diagnosis of NSCLCs, selecting treatment protocols, and
predicting the prognosis of patients with NSCLCs.
lncRNAs in the therapeutic resistance of NSCLCs
At present, surgical excision, chemotherapy, chest radiother-
apy and targeted therapy are used alone or in combination
to treat patients with NSCLC [94]. However, drug therapies
fail in most NSCLCs due to development of drug resistance
[95]. Studies have suggested an important role of dysregulated
miRNAs in the development of drug resistance [96]. Addi-
tional studies also have demonstrated the association between
the expression of certain lncRNAs and chemotherapeutic
sensitivity of cancer cells. For instance, H19 induced
P-glycoprotein- and MDR1-associated drug resistance in
liver cancer cells [97].
Resistance to cisplatin, carboplatin, and EGFR-TKIs is
inevitable in treating NSCLCs [98]. In an effort to explore
the molecular mechanisms of cisplatin resistance, Yang et al
found 1380 lncRNAs differentially expressed between regular
A549 and cisplatin-resistant A549 cells, indicating the possible
involvement of lncRNAs in cisplatin resistance. The authors
identified a novel lncRNA, AK126698, which confers cisplatin
resistance by targeting the Wnt pathway [82]. Likewise, other
research groups showed that HOTAIR contributed to cisplatin
resistance of NSCLC cells by downregulating p21WAF1/CIP1
expression [99] and that MEG3 mediated cisplatin resistance
of NSCLC cells by regulating the expression of p53 and Bcl-
xL [78]. Patients with low MEG3 expression showed poor
Table 1 NSCLC-associated lncRNAs
lncRNA Expression Key factors Functions Ref.
CAR10 Up YB-1 Promote cell proliferation [53]
MALAT1 Up SR, PC2, hnRNP C Promote cell proliferation, migration, and invasion [54]
HOTAIR Up PRC2, LSD1 Promote cell proliferation, invasion, and metastasis [55]
H19 Up miR-675, c-MYC, p53 Suppress apoptosis
Promote cell growth
[56]
RGMBAS1 Up RGMB Promote cell metastasis [57]
PVT1 Up Promote cell proliferation, migration, and invasion [58]
GHSROS Up Promote cell migration [59]
NKX2-AS1 Up EZH2, UTX Promote cell growth,
Regulate cell shape
[60]
BCYRN1 Up c-MYC Promote cell motility, migration, and invasion [61]
DLX6-AS1 Up DLX6 Carcinogenesis [62]
AFAP1-AS1 Up Actin filament integrity Promote cancer cell metastasis [63]
SOX2-OT Up PRC2 Promote cell proliferation [64]
CARLo-5 Up Promote cell proliferation, migration, and
invasion,
[65]
Lnc_bc060912 Up PARP1, NPM1 Repress cell apoptosis [66]
MVIH Up Promote cell proliferation and invasion [67]
HNF1A-AS1 Up DNMT1 Promote tumor proliferation and metastasis [68]
CCAT2 Up Promote cell proliferation and invasion [69]
LUADT1 Up SUZ12, p27, LUAD Regulate cell cycle [70]
ZXF1 Up Promote cell invasion and metastasis [71]
ANRIL Up PRC2 Correlate with TNM stages and tumor size [72]
SCAL1 Up Nrf-2 Mediate oxidative stress protection [52]
NRG1 Up Carcinogenesis [73]
DQ786227 Up Mediate oxidative stress protection [50]
LOC728228 Up Mediate oxidative stress protection [51]
GAS5 Down p53, E2F1, miR-21 Induce apoptosis, drug resistance [74]
GAS6-AS1 Down Suppress metastasis [75]
PANDAR Down p53, NF-YA, Bcl-2 Repress cell proliferation [76]
HMlincRNA717 Down Associate with lymph node metastasis [77]
MEG3 Down P53 Suppress cell proliferation, Induce apoptosis [78]
TUG1 Down P53, PRC2 Suppress cell proliferation [79]
SPRY4-IT1 Down PRC2 Induce apoptosis, Suppress cell proliferation [80]
BANCR Down Suppress cell proliferation, Induce apoptosis [81]
AK126698 Down Wnt pathway Mediate cisplatin resistance [82]
Note: AFAP1-AS1, actin filament associated protein 1 antisense RNA 1; ANRIL, antisense noncoding RNA in the INK4 locus; BANCR, BRAF-
activated non-coding RNA; BCYRN1, brain cytoplasmic RNA 1; CAR10, chromatin associated RNA intergenic 10; CARLo-5, also known as
colon cancer associated transcript 1 (CCAT1); CCAT2, colon cancer associated transcript 2; DLX6, distal-less homeobox 6; DLX6-AS1, distal-less
homeobox 6 antisense RNA 1; DNMT1, DNA methyltransferase 1; EZH2, enhancer of Zeste homolog 2; GAS5, growth arrest-specific transcript
5; GAS6-AS1, growth arrest-specific transcript 6 antisense RNA 1; GHSROS, growth hormone secretagogue receptor opposite strand; HNF1A-
AS1, HNF1 homeobox A antisense RNA 1; hnRNP C, heterogeneous nuclear ribonucleoprotein C; HOTAIR: Hox antisense intergenic RNA;
lncRNA, long non-coding RNA; LSD1, lysine-specific demethylase 1; LUADT1, lung adenocarcinoma associated transcript 1; MALAT1,
metastasis associated lung adenocarcinoma transcript 1; MEG3, maternally expressed gene 3; MVIH, microvascular invasion in HCC; NF-YA, A
subunit of nuclear factor-Y; NKX2-AS1, NK2 homeobox-1 antisense RNA 1; NPM1, nucleophosmin 1; Nrf-2, NF-E2-related factor 2; NRG1,
nickel-related gene 1; NSCLC, non-small-cell lung cancer; PANDAR, promoter of CDKN1A antisense DNA damage activated RNA; PARP1,
poly (ADP-ribose) polymerase 1; PC2, subtilisin-related proprotein convertases 2; PRC2, polycomb repressive complex 2; PVT1, plasmacytoma
variant translocation 1; RGMB, repulsive guidance molecule b; RGMBAS1, repulsive guidance molecule b antisense RNA1; SCAL1, smoke and
cancer-associated lncRNA-1; SOX2-OT, SRY-box 2 overlapping transcript; SPRY4-IT1, SPRY4 intronic transcript 1; SR, serine/arginine RNA
splicing protein; SUZ12, suppressor of Zeste 12; TUG1, taurine-upregulated gene 1; UTX, lysine demethylase 6A; YB-1, Y-box-binding protein 1;
ZXF1, as known as ACTA2 antisense RNA 1 (ACTA2-AS1).
284 Genomics Proteomics Bioinformatics 14 (2016) 280–288response to cisplatin-based chemotherapy [78]. Notably, the
effectiveness of cisplatin against LSCCs varied between indi-
viduals due to different gene expression profiles [100]. For
instance, cisplatin-based chemotherapy was beneficial for
LSCC patients with excision repair cross-complementation
group 1 (ERCC1)-negative tumors after surgical operation,
but not for LSCC patients with ERCC1-positive tumors
[101]. Hou et al identified 1702 lncRNAs that were differen-
tially expressed between cisplatin-sensitive and cisplatin-resistant LSCC patients. In particular, the expression of
AC006050.3-003 was significantly downregulated in patients
showing sensitivity to cisplatin compared with those with resis-
tance to cisplatin, suggesting that AC006050.3-003 may be a
biomarker for cisplatin treatment in patients with LSCCs
[102]. In addition, Dong et al found that GAS5 enhanced the
sensitivity of cells expressing wild-type EGFR to gefitinib
treatment [103]. These studies demonstrate the correlations
between lncRNAs and drug resistance, providing additional
Wei MM and Zhou GB / lncRNAs in Lung Cancer 285opportunities to overcome drug resistance by targeting
lncRNAs and related signaling pathways.Conclusions and perspectives
With the development of technological approaches, such as
lncRNA microarray and RNA sequencing, more and more
lncRNAs have been found to be dysregulated in NSCLCs,
which function as oncogenes or tumor suppressors. Some of
these lncRNAs are associated with different stages of
NSCLCs, some are specifically overexpressed in one of the
lung cancer subtypes, and some are involved in drug resistance.
These findings suggest the important roles of lncRNAs in the
pathogenesis and treatment of NSCLCs. However, only a
small number of lncRNAs have been well characterized,
whereas functions of most lncRNAs remain to be elucidated.
Many key questions still need to be addressed. For exam-
ple, how lncRNAs regulate downstream pathways? Can we
use lncRNAs as predictive markers for lung cancer risk or as
early diagnostic or prognostic markers? How do lncRNAs
mediate drug resistance? Can we use lncRNAs as appropriate
therapeutic targets, how to target them if yes? How do we deli-
ver the therapeutic lncRNAs into target tissues and evaluate
their safety? Answers to these and other questions will provide
new insights into the pathogenesis of lung cancers and help
optimize therapeutic strategies to improve the clinical outcome
of this deadly disease, which causes 1.59 million deaths each
year worldwide [104].Competing interests
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